
AtkinsRéalis, EDF pursue tighter partnership as they seek to build new nuclear plants
Montreal-based engineering company AtkinsRéalis Group Inc. ATRL-T and Électricité de France, the French nuclear giant, have agreed to pursue a deeper partnership, the companies declared Monday.
The two nuclear companies are preparing for what they hope will be a global surge in reactor construction. Their new collaboration agreement could lead to supplying power-plant equipment, such as turbines, and providing engineering support.
Joe St. Julian, president of AtkinsRéalis's nuclear operations, has predicted that as many as 1,000 new reactors will be built by mid-century; he said his company is responding to concerns from customers and government about whether it has sufficient capacity to capture a sizable chunk of that demand.
'We don't know if we're going to need them or their capacity in engineering,' he said of EDF. 'But if we do, we want to have them as a readily available partner.'
Meta signs 20-year deal with nuclear plant to meet energy demands for AI
Nuclear stocks surge after Trump signs orders to boost industry
The two companies have worked together before; EDF is AtkinsRéalis's second-largest customer, behind Ontario Power Generation.
Owned entirely by the French government, EDF operates the largest reactor fleet of any single company worldwide: 57 in France, and nine in Britain. It's also lead contractor on two large plants under construction in Britain: Hinkley Point C and Sizewell C.
AtkinsRéalis is the architect and engineer on both projects. Mr. St. Julian said negotiations began six months ago on the collaboration agreement, which is non-binding and can be terminated by either party at will. Both companies agree they'll continue competing with each other to sell their own respective reactor models.
AtkinsRéalis holds an exclusive licence for Canada's Candu reactor; it's marketing the 740-megawatt Enhanced Candu 6 along with a proposed 1,000-megawatt model called the Monark.
The company has been searching for a turbine generator set to pair with the Monark. (Candus have traditionally been paired with American-built turbines from General Electric.) The company has shortlisted turbines from Arabelle Solutions, which became an EDF subsidiary a year ago and has roots in France dating from the 1950s.
'We really like the EDF turbine generator,' Mr. St. Julian said. 'And as we started that discussion, we recognized there's opportunities for us to take this already robust industrial partnership and expand it, where we help you guys in Europe, maybe, and you guys can help us in Canada, maybe.'
The European Pressurized Reactor (EPR) – which EDF is building at Hinkley Point and Sizewell – is much larger than the Monark, at 1,600 megawatts. In 2023, Ontario Power Generation and EDF said they were jointly exploring the feasibility of building EPRs in Canada.
Nuclear-power generation is tightly concentrated in a handful of countries, and France is among them. It once boasted the world's second-largest operating fleet but has been eclipsed by China, which stands nearly alone in aggressively adding new nuclear capacity.
Despite recent optimism about a nuclear 'renaissance,' other technologies (including renewables and fossil fuels) continue to attract far more investment, the International Energy Agency said in a report published last week.
Capital flows directed to nuclear power have grown by half over the past five years, the IEA noted, but Chinese investment accounted for most of that increase.
Although the French government continues to express enthusiasm for building new nuclear plants, EDF's reactor fleet is aging. France's only new plant so far this century, the 1.65-gigawatt Flamanville Unit 3, was connected to the grid in December. Its construction began as long ago as 2007 but was plagued by immense cost and schedule overruns. EDF carries a heavy debt load, which is widely expected to present a major obstacle for future projects.
According to Paris-based Mycle Schneider Consulting's latest report on the nuclear industry, EDF also faces 'technical and manpower challenges with their existing ageing nuclear fleets and ongoing construction projects.' The Korea Electric Power Corp. is also highly indebted, while major Chinese and Russian builders have been subject to international sanctions and blacklists.
'Who is supposed to build hundreds of nuclear power reactors around the world over the coming two and a half decades?' the consultancy asked.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
4 hours ago
- CTV News
Canadian safety institute announces research projects as global focus shifts to AI adoption
Innovation, Science and Industry Minister Francois-Philippe Champagne, right, and founder and scientific director of MILA-Quebec Artificial Intelligence Institute Yoshua Bengio answer media questions following the launch the Canadian Artificial Intelligence Safety Institute in Montreal on Tuesday, Nov. 12, 2024. THE CANADIAN PRESS/Christinne Muschi OTTAWA — The Canadian Artificial Intelligence Safety Institute will fund research projects focusing on misinformation, generative AI and the safety of autonomous systems. It says the initial 10 projects will receive $100,000 each from its research program. They include an initiative led by AI pioneer Yoshua Bengio that will look at the hidden reasons driving decisions by large language models, a type of generative AI focused on text. The Canadian AI Safety Institute was launched last year, part of a global network of publicly backed safety institutes that emerged following a wave of calls from experts for AI regulation. But there has been a global shift towards focusing on AI adoption over safety initiatives in recent months. In Canada, the Liberal government plans to prioritize AI's economic potential as it hosts the upcoming G7 summit, and new AI minister Evan Solomon has said nothing so far about his job description. Article by Anja Karadeglija.


Globe and Mail
5 hours ago
- Globe and Mail
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024. The recent spree of acquisitions signifies a focus on portfolio expansion and constant pipeline innovation, given the changing landscape and spotlight on AI-driven drug discovery. Simultaneously, bigwigs in the space also enter into licensing deals and collaborations for a promising drug/candidate to strengthen and expand their portfolios in their respective core areas. Quick Take on Recent Acquisitions & Deals Pharma giant Sanofi SNY recently announced that it will acquire Blueprint Medicines for a total deal value of up to $9.5 billion to expand its portfolio in rare immunological disease and add an early-stage pipeline in immunology. The impending acquisition will add Blueprint Medicines' only marketed product, Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, to Sanofi's commercial portfolio. Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BioNTech will also receive $2 billion in non-contingent anniversary payments through 2028. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment, attracting other pharma giants as well. In May 2025, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are also being eyed. Last week, Regeneron REGN entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. M&A in Focus in 2025 Consolidation has long been a central focus in the pharma/biotech industry. This is because leading companies constantly look to diversify their revenue base in the face of dwindling sales of their high-profile drugs. Acquisitions also make sense as developing a drug/technology from scratch is costly and risky. In April, pharma giant Johnson & Johnson acquired Intra-Cellular Therapies for approximately $14.6 billion and added antidepressant drug, Caplyta, to its neuroscience portfolio. Swiss pharma bigwig Novartis NVS, too, has been on an acquisition spree. Novartis is all set to acquire San Diego-based clinical-stage biopharmaceutical company Regulus Therapeutics to strengthen its renal disease portfolio. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. In April, Germany-based Merck KGaA announced that it will acquire SpringWorks Therapeutics, Inc. for $3.9 billion to expand business in the United States. SpringWorks Therapeutics, a U.S.-based biopharma company, has a portfolio that comprises a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas. Potential Deals We expect M&A activity to accelerate further in 2025, given the massive cash reserve owned by major pharma and biotech companies. These companies will also look to utilize innovative technology to develop breakthrough treatments rapidly as the landscape evolves. Moreover, smaller biotechs often lack the necessary funds to successfully develop a drug and commercialize thereafter. The recent spotlight on the usage of AI technology for drug discovery should lure investment in this industry. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report


CTV News
6 hours ago
- CTV News
Montreal home sales, prices rise in May despite steady rates and economic uncertainty
Home sales in the Montreal-area rose again in May compared with the same month a year ago, as the city's real estate board says both activity and price growth show no signs of tapering off. A real estate sign shows a home for sale in Montreal on Monday, March 24, 2025. THE CANADIAN PRESS/Christinne Muschi MONTREAL — Home sales in the Montreal-area rose again in May compared with the same month a year ago, as the city's real estate board says both activity and price growth show no signs of tapering off. The Quebec Professional Association of Real Estate Brokers says 4,992 homes in the region changed hands last month, up 10.2 per cent from 4,532 sales in May 2024. Charles Brant, the board's market analysis director, says it marks the third straight month of similar year-over-year sales growth despite mortgage rates remaining in a holding pattern and 'ongoing economic uncertainty.' Brant says there are also 'no signs of a lull in price growth' as around one in seven homes sold above the asking price last month. The median price for all housing types in the Montreal area was up year-over-year, led by an 8.7 per cent increase in price of a single-family home to $625,000. The median price of a plex rose 5.1 per cent to $825,000 and the median price of a condominium increased 4.3 per cent to $427,500. There were 7,596 new listings in the Montreal area last month, up 11.2 per cent from a year earlier, as active listings rose 2.4 per cent to 18,920. This report by The Canadian Press was first published June 9, 2025.